Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Trial of Pulse Dosed Ceftriaxone for Post-Treatment Lyme Disease

NCT06785402 is registered in ClinicalTrials.gov with Hackensack Meridian Health as lead sponsor.

NCT NCT06785402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06785402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Trial of Pulse Dosed Ceftriaxone for Post-Treatment Lyme Disease
Lead sponsor
Hackensack Meridian Health
Phase
Phase 1/2
Overall status
Withdrawn
Start date
May 14, 2026
Completion date
May 14, 2026
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

post-treatment lyme disease syndrome